Biotech Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Private, Subsidiary
- Established
- 2000-08-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biotechplc.com
A Phase I Clinical Trial of JH013 Injection
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06633055
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06343116
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06333821
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05986162
Safety and Preliminary Clinical Activity of Itolizumab in ARDS
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05978544
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 354
- Registration Number
- NCT05978050
- Locations
- 🇨🇳
National Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Clinical Activity of Itolizumab in aGVHD
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05823675
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05278728
- Locations
- 🇨🇳
China People's Liberation Army (PLA)81 Hospital, Nanjing, Jiangsu, China
🇨🇳Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1931
- Registration Number
- NCT04949503
- Locations
- 🇨🇳
First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shannxi, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04532229
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital of Centre-south University, Changsha, Hunan, China
© Copyright 2024. All Rights Reserved by MedPath